Anika Therapeutics CEO Dr. Cheryl Blanchard to Present at 43rd Annual J.P. Morgan Healthcare Conference
Anika Therapeutics CEO Dr. Cheryl Blanchard to Present at 43rd Annual J.P. Morgan Healthcare Conference
The presentation will be webcast live on the Events and Webcasts page on Anika Therapeutics' website.Anika Therapeutics' CEO will present at the J.P. Morgan Healthcare Conference on January 16, 2025, and meet investors.
阿尼卡疗法的首席执行官将在2025年1月16日的摩根大通医疗会议上进行演讲，并与投资者会面。
Quiver AI Summary
Quiver AI 概要
Anika Therapeutics, Inc. has announced that Dr. Cheryl Blanchard, the company's President and CEO, will present at the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco on January 16, 2025, at 9:45 am PT. The presentation will be available for live streaming and will also be archived for 30 days on the company's website. Additionally, Anika's management will hold one-on-one investor meetings during the event. Anika Therapeutics is focused on joint preservation in early intervention orthopedics, specializing in products that utilize hyaluronic acid and implant solutions to enhance orthopedic care, particularly in managing osteoarthritis pain and regenerative solutions. The company is headquartered near Boston, Massachusetts.
阿尼卡疗法公司宣布，公司的总裁兼首席执行官Cheryl Blanchard博士将在2025年1月16日上午9:45（太平洋时间）于旧金山举行的第43届年度摩根大通医疗会议上进行演讲。该演讲将可通过直播观看，并将在公司网站上存档30天。此外，阿尼卡的管理层将在活动期间举行一对一的投资者会议。阿尼卡疗法专注于早期干预骨科中的关节保护，专门开发利用透明质酸和植入解决方案的产品，以增强骨科护理，特别是在管理骨关节炎疼痛和再生解决方案方面。该公司总部位于马萨诸塞州波士顿附近。
Potential Positives
潜在的积极因素
- Participation in the prestigious 43rd Annual J.P. Morgan Healthcare Conference highlights Anika Therapeutics' credibility and position within the healthcare sector.
- Live webcast of the presentation increases visibility and access for investors and stakeholders, showcasing the company's commitment to transparency.
- One-on-one investor meetings provide an opportunity for direct engagement with management, potentially strengthening investor relations and interest in the company.
- 参与这一享有声望的第43届年度摩根大通医疗会议突显了阿尼卡疗法在医疗领域的信誉和地位。
- 演讲的直播提高了投资者和利益相关者的可见性和访问权限，展示了公司对透明度的承诺。
- 一对一的投资者会议提供了与管理层直接接触的机会，有助于增强投资者关系和对公司的兴趣。
Potential Negatives
潜在负面因素
- None
- 无
FAQ
常见问题
When is Anika Therapeutics presenting at the J.P. Morgan Healthcare Conference?
阿尼卡疗法将于何时在摩根士丹利医疗会议上发表演讲？
Anika Therapeutics will present on January 16, 2025, at 9:45 am PT / 12:45 pm ET.
阿尼卡疗法将于2025年1月16日上午9:45（太平洋时间）/ 下午12:45（东部时间）进行演讲。
Where can I watch the Anika Therapeutics presentation?
我在哪里可以观看阿尼卡疗法的演讲？
The presentation will be webcast live on the Events and Webcasts page on Anika Therapeutics' website.
此次演讲将在阿尼卡疗法官方网站的活动与直播页面进行直播。
Who is Dr. Cheryl Blanchard?
谢丽尔·布兰查德博士是谁？
Dr. Cheryl Blanchard is the President and CEO of Anika Therapeutics.
谢丽尔·布兰查德博士是阿尼卡疗法的总裁兼首席执行官。
How can I schedule a meeting with Anika's management?
我如何才能安排与阿尼卡疗法管理层的会议？
To schedule a meeting, contact Anika's Investor Relations at investorrelations@anika.com.
要安排会议，请联系阿尼卡疗法的投资者关系部门，邮箱是 investorrelations@anika.com。
What does Anika Therapeutics focus on?
阿尼卡疗法专注于什么？
Anika Therapeutics focuses on joint preservation and early intervention in orthopedic care, including Osteoarthritis Pain Management.
阿尼卡疗法专注于关节保护和骨科护理的早期干预，包括骨关节炎疼痛管理。
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
免责声明：这是由GlobeNewswire分发的新闻稿的人工智能生成摘要。用于总结这份稿件的模型可能会出错。请在这里查看完整发布。
$ANIK Hedge Fund Activity
$ANIk 对冲基金活动
We have seen 47 institutional investors add shares of $ANIK stock to their portfolio, and 68 decrease their positions in their most recent quarter.
我们看到47家机构投资者在最近一个季度中增加了对$ANIk股票的持有，68家机构减少了他们的头寸。
Here are some of the largest recent moves:
以下是最近的一些重大变动：
- BLACKROCK, INC. added 157,707 shares (+9.8%) to their portfolio in Q3 2024
- RIVERWATER PARTNERS LLC added 86,037 shares (+539.1%) to their portfolio in Q3 2024
- AQR CAPITAL MANAGEMENT LLC removed 76,681 shares (-71.4%) from their portfolio in Q3 2024
- NUVEEN ASSET MANAGEMENT, LLC removed 58,761 shares (-58.7%) from their portfolio in Q3 2024
- MORGAN STANLEY removed 49,011 shares (-9.8%) from their portfolio in Q3 2024
- CITADEL ADVISORS LLC removed 47,063 shares (-52.8%) from their portfolio in Q3 2024
- VIRTUS INVESTMENT ADVISERS, INC. removed 45,579 shares (-100.0%) from their portfolio in Q3 2024
- 贝莱德公司在2024年第三季度增加了157,707股 (+9.8%) 到他们的投资组合中
- RIVERWATER PARTNERS LLC在2024年第三季度增加了86,037股 (+539.1%) 到他们的投资组合中
- AQR资本管理公司在2024年第三季度从他们的投资组合中移除了76,681股 (-71.4%)
- NUVEEN资产管理公司在2024年第三季度从他们的投资组合中移除了58,761股 (-58.7%)
- 摩根士丹利在2024年第三季度从他们的投资组合中移除了49,011股 (-9.8%)
- CITADEL顾问公司在2024年第三季度从他们的投资组合中移除了47,063股 (-52.8%)
- 维德思投资顾问公司在2024年第三季度从他们的投资组合中移除了45,579股 (-100.0%)
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
要跟踪对冲基金的股票投资组合，请查看Quiver Quantitative的机构持有情况仪表。
Full Release
完整发布
BEDFORD, Mass., Dec. 23, 2024 (GLOBE NEWSWIRE) --
Anika Therapeutics, Inc.
(NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, today announced that Dr. Cheryl Blanchard, President and CEO of Anika, will present at the 43
rd
Annual J.P. Morgan Healthcare Conference in San Francisco on Thursday, January 16, 2025 at 9:45am PT / 12:45pm ET. Management will also participate in one-on-one investor meetings throughout the event.
马萨诸塞州贝德福德，2024年12月23日（全球新闻网） --
阿尼卡疗法公司
（纳斯达克：ANIK），一家专注于早期干预骨科的全球关节保护公司，今天宣布阿尼卡的董事长兼首席执行官雪莉·布兰查德博士将在第43届
rd
雅培摩根医疗保健大会上发言，会议将于2025年1月16日星期四上午9:45（太平洋时间） / 下午12:45（东部时间）在旧金山举行。管理层还将在整个活动期间参与一对一的投资者会议。
The presentation will be webcast live on the
Events and Webcasts page
under the Investors section of Anika Therapeutics' website and will be archived for 30 days following the presentation. For more information about this event or to schedule a one-on-one meeting with Anika's senior management, please contact Anika's Investor Relations at
investorrelations@anika.com
.
此次演讲将通过
活动和网络直播页面现场直播
在阿尼卡疗法官网的投资者专区，将在展示后保存30天。有关于该活动的更多信息或想安排与阿尼卡高级管理层的一对一会议，请联系阿尼卡的投资者关系部门，
investorrelations@anika.com
.
About Anika
Anika Therapeutics, Inc.
(NASDAQ: ANIK), is a global joint preservation company that creates and delivers meaningful advancements in early intervention orthopedic care. Leveraging our core expertise in hyaluronic acid and implant solutions, we partner with clinicians to provide minimally invasive products that restore active living for people around the world. Our focus is on high opportunity spaces within orthopedics, including Osteoarthritis Pain Management and Regenerative Solutions, and our products are efficiently delivered in key sites of care, including ambulatory surgery centers. Anika's global operations are headquartered outside of Boston, Massachusetts. For more information about Anika, please visit
.
关于阿尼卡
阿尼卡疗法公司
(纳斯达克: ANIK)是一家全球关节保护公司，致力于创造并提供早期干预骨科护理的重大进展。我们利用在透明质酸和植入解决方案方面的核心专业知识，与临床医生合作，提供微创产品，以恢复全球人们的积极生活。我们的重点是骨科领域内高机会的空间，包括骨关节炎疼痛管理和再生解决方案，我们的产品在关键护理场所（包括门诊手术中心）高效交付。阿尼卡的全球业务总部位于马萨诸塞州波士顿附近。有关阿尼卡的更多信息，请访问
.
ANIKA, ANIKA THERAPEUTICS, CINGAL, HYALOFAST, INTEGRITY, MONOVISC, ORTHOVISC, TACTOSET, and the Anika logo are trademarks of Anika Therapeutics, Inc. or its subsidiaries or are licensed to Anika Therapeutics, Inc. for its use.
ANIKA、阿尼卡疗法、CINGAL、HYALOFASt、INTEGRITY、MONOVISC、ORTHOVISC、TACTOSEt及阿尼卡标志均为阿尼卡疗法公司或其子公司的商标，或已授权给阿尼卡疗法公司使用。
For Investor Inquiries:
Anika Therapeutics, Inc.
Matt Hall, 781-457-9554
Director, Corporate Development and Investor Relations
investorrelations@anika.com
投资者咨询：
阿尼卡疗法公司
马特·霍尔，781-457-9554
董事，企业发展和投资者关系
investorrelations@anika.com
